Retention of clinical trial participants in a study of Nongonococcal Urethritis (NGU), a sexually transmitted infection in men

Contemporary Clinical Trials

Volumn 33, Issue 4, 2012, Pages 606-610

  Lee, Jeannette Y ^a   Lensing, Shelly Y ^a   Schwebke, Jane R ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Clinical trial retention; Nongonococcal urethritis; Sexually transmitted infections

Indexed keywords

AZITHROMYCIN; DOXYCYCLINE; TINIDAZOLE;

ACADEMIC ACHIEVEMENT; ADD ON THERAPY; ADULT; AFRICAN AMERICAN; ARTICLE; CHLAMYDIA TRACHOMATIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTICIPATORY RESEARCH; RANDOMIZED CONTROLLED TRIAL; SEXUALLY TRANSMITTED DISEASE; TREATMENT DURATION; URETHRITIS;

ADOLESCENT; ADULT; AFRICAN AMERICANS; ANTI-INFECTIVE AGENTS; AZITHROMYCIN; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DOXYCYCLINE; DRUG THERAPY, COMBINATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SOCIOECONOMIC FACTORS; TINIDAZOLE; URETHRITIS; YOUNG ADULT;

EID: 84862813640     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2011.12.004     Document Type: Article

References (40)

1. Schwebke J.R., Rompalo A., Taylor S., Sena Ac., Martin D.H., Lopez L.M., et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens-a randomized clinical trial. Clin Infect Dis 2011, 52(2):163-170.
2. Peipert J.F. Clinical practice. Genital chlamydial infections. N Engl J Med 2003, 349(25):2424-2430.
3. Gaydos C., Maldeis N.E., Hardick A., Hardick J., Quinn T.C. Mycoplasma genitalium compared to chlamydia, gonorrhoea and trichomonas as an aetiological agent of urethritis in men attending STD clinics. Sex Transm Infect 2009, 85(6):438-440.
4. Wetmore C.M., Manhart L.E., Lowens M.S., Golden M.R., Whittington W.L., Xet-Mull A.M., et al. Demographic, behavioral, and clinical characteristics of men with nongonococcal urethritis differ by etiology: a case-comparison study. Sex Transm Dis 2011, 38(3):180-186.
5. Centers for Disease Control and Prevention, Sexually Transmitted Disease Surveillance 2009, U.S. Department of Health and Human Services, Editor 2010: Atlanta, Georgia.
6. Newman L.M., Warner L., Weinstock H.S. Predicting subsequent infection in patients attending sexually transmitted disease clinics. Sex Transm Dis 2006, 33(12):737-742.
7. Gifford A.L., Cunningham W.E., Heslin K.C., Andersen R.M., Nakazono T., Lieu D.K., et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med 2002, 346(18):1373-1382.
8. Colon-Otero G., Smallridge R.C., Solberg L.A., Keith T.D., Woodward T.A., Willis F.B., et al. Disparities in participation in cancer clinical trials in the United States: a symptom of a healthcare system in crisis. Cancer 2008, 112(3):447-454.
9. Murthy V.H., Krumholz H.M., Gross C.P. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004, 291(22):2720-2726.
10. Stewart J.H., Bertoni A.G., Staten J.L., Levine E.A., Gross C.P. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol 2007, 14(12):3328-3334.
11. Lara P.N., Paterniti D.A., Chiechi C., Turrell C., Morain C., Horan N., et al. Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol 2005, 23(36):9282-9289.
12. Ford J.G., Howerton M.W., Lai G.Y., Gary T.L., Bolen S., Gibbons M.C., et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 2008, 112(2):228-242.
13. Brown M., Moyer A. Predictors of awareness of clinical trials and feelings about the use of medical information for research in a nationally representative US sample. Ethn Health 2010, 15(3):223-236.
14. Carey M.P., Senn T.E., Vanable P.A., Coury-Doniger P., Urban M.A. Do STD clinic patients who consent to sexual health research differ from those who decline? Findings from a randomized controlled trial with implications for the generalization of research results. Sex Transm Dis 2008, 35(1):73-77.
15. Gwadz M.V., Colon P., Ritchie A.S., Leonard N.R., Cleland C.M., Riedel M., et al. Increasing and supporting the participation of persons of color living with HIV/AIDS in AIDS clinical trials. Curr HIV/AIDS Rep 2010, 7(4):194-200.
16. Newman P.A., Duan N., Roberts K.J., Seiden D., Rudy E.T., Swendeman D., et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr 2006, 41(2):210-217.
17. Katz R.V., Kegeles S.S., Kressin N.R., Green B.L., Wang M.Q., James S.A., et al. The Tuskegee Legacy Project: willingness of minorities to participate in biomedical research. J Health Care Poor Underserved 2006, 17(4):698-715.
18. Chou B., Krill L.S., Horton B.B., Barat C.E., Trimble C.L. Disparities in human papillomavirus vaccine completion among vaccine initiators. Obstet Gynecol 2011, 118(1):14-20.
19. DeVita D.A., White M.C., Zhao X., Kaidarova Z., Murphy E.L. Determinants of subject visit participation in a prospective cohort study of HTLV infection. BMC Med Res Methodol 2009, 9:19.
20. Magruder K.M., Bichun O., Miller S., Tilley B.C. Retention of under-represented minorities in drug abuse treatment studies. Clin Trials 2009, 6(3):252-260.
21. Akl E.A., Briel M., You J.J., Lamontagne F., Gangji A., Cukierman-Yaffe T., et al. LOST to follow-up Information in Trials (LOST-IT): a protocol on the potential impact. Trials 2009, 10:40.
22. Hamasuna R., Takahashi S., Kiyota H., Yasuda M., Hayami H., Arakawa S., et al. Effect of gatifloxacin against mycoplasma genitalium-related urethritis: an open clinical trial. Sex Transm Infect 2011, 87(5):389-390.
23. Stamm W.E., Batteiger B.E., McCormack W.M., Totten P.A., Sternlicht A., Kivel N.M. A randomized, double-blind study comparing single-dose rifalazil with single-dose azithromycin for the empirical treatment of nongonococcal urethritis in men. Sex Transm Dis 2007, 34(8):545-552.
24. Mena L.A., Mroczkowski T.F., Nsuami M., Martin D.H. A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma genitalium-positive urethritis in men. Clin Infect Dis 2009, 48(12):1649-1654.
25. Golden M.R., Whittington W.L., Handsfield H.H., Hughes J.P., Stamm W.E., Hogben M., et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005, 352(7):676-685.
26. Thurman A.R., Holden A.E., Shain R.N., Perdue S., Piper J.M. Preventing recurrent sexually transmitted diseases in minority adolescents: a randomized controlled trial. Obstet Gynecol 2008, 111(6):1417-1425.
27. Feldblum P.J., Halpern V., Lie C.C., Obunge O., Ogunsola F., Ampofo W., et al. What predicts non-retention in microbicide trials?. Contemp Clin Trials 2011, 32(4):512-516.
28. Wendler D., Krohmal B., Emanuel E.J., Grady C. Why patients continue to participate in clinical research. Arch Intern Med 2008, 168(12):1294-1299.
29. Hessol N.A., Weber K.M., Holman S., Robison E., Goparaju L., Alden C.B., et al. Retention and attendance of women enrolled in a large prospective study of HIV-1 in the United States. J Womens Health (Larchmt) 2009, 18(10):1627-1637.
30. de Bruyn G., Hudgens M.G., Sullivan P.S., Duerr A.C. Participant retention in clinical trials of candidate HIV vaccines. J Acquir Immune Defic Syndr 2005, 39(4):499-501.
31. Fortune T., Wright E., Juzang I., Bull S. Recruitment, enrollment and retention of young black men for HIV prevention research: experiences from The 411 for Safe Text project. Contemp Clin Trials 2010, 31(2):151-156.
32. Howe C.J., Cole S.R., Napravnik S., et al. Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007. AIDS Res Hum Retroviruses 2010, 26(8):875-881.
33. Osann K., Wenzel L., Dogan A., Hsieh S., Chase D.M., Sappington S., et al. Recruitment and retention results for a population-based cervical cancer biobehavioral clinical trial. Gynecol Oncol 2011, 121(3):558-564.
34. Abdool Karim Q, Abdool Karim S.S., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329(5996):1168-1174.
35. Abdool Karim S.S., Richardson B.A., Ramjee G., Hoffman I.F., Chirenje A.M., Taha T., et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 2011, 25(7):957-966.
36. Leichliter J.S., Chesson H.W., Sternberg M., Aral S.O. The concentration of sexual behaviours in the USA: a closer examination of subpopulations. Sex Transm Infect 2010, 86(Suppl. 3):iii45-iii51.
37. Caldwell P.H., Hamilton S., Tan A., Craig J.C. Strategies for increasing recruitment to randomised controlled trials: systematic review. PLoS Med 2010, 7(11):1-16.
38. Colfax G., Buchbinder S., Vamshidar G., Celum C., McKirnan D., Neidig J., et al. Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2005, 39(3):359-364.
39. Seal K.H., Kral A.H., Lorvick J., McNees A., Gee L., Edlin B.R. A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend 2003, 71(2):127-131.
40. Kamb M.L., Rhodes F., Hoxworth T., Rogers J., Lentz A., Kent C., et al. What about money? Effect of small monetary incentives on enrollment, retention, and motivation to change behaviour in an HIV/STD prevention counselling intervention. The Project RESPECT Study Group. Sex Transm Infect 1998, 74(4):253-255.